Home » Stocks » SPRB

Spruce Biosciences, Inc. (SPRB)

Stock Price: $22.00 USD 0.28 (1.29%)
Updated Jan 25, 2021 4:00 PM EST - Market closed
Market Cap 505.22M
Revenue (ttm) n/a
Net Income (ttm) -17.35M
Shares Out 22.26M
EPS (ttm) -0.78
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day January 25
Last Price $22.00
Previous Close $21.72
Change ($) 0.28
Change (%) 1.29%
Day's Open 21.75
Day's Range 21.01 - 22.42
Day's Volume 15,385
52-Week Range 15.38 - 32.42

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation
Business Wire - 2 weeks ago

SAN FRANCISCO--(BUSINESS WIRE)---- $SPRB #CAH--Spruce Biosciences Provides Corporate Update and Outlines Milestones for 2021

Business Wire - 1 month ago

SAN FRANCISCO--(BUSINESS WIRE)---- $SPRB #CAH--Spruce Biosciences Added to Russell 2000®, 3000® and Microcap® Indexes

Business Wire - 2 months ago

SAN FRANCISCO--(BUSINESS WIRE)---- $SPRB #CAH--Spruce Biosciences Reports Third Quarter 2020 Financial Results and Provides Corporate Update

Business Wire - 2 months ago

SAN FRANCISCO--(BUSINESS WIRE)---- $SPRB #CAH--Spruce Biosciences to Participate in the Credit Suisse 29th Annual Virtual Healthcare Conference

Seeking Alpha - 2 months ago

After a fast and furious week of activity, the IPO market is slated for a brief intermission in the coming week due to the approaching presidential election. Currently, there are no regular wa...

Other stocks mentioned: AYLA, FUBO, GAN, INTZ, KC, KRON, STTK
Business Wire - 3 months ago

SAN FRANCISCO--(BUSINESS WIRE)---- $SPRB #CAH--Spruce Biosciences Announces Closing of Upsized Initial Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares

Seeking Alpha - 3 months ago

U.S. IPO Weekly Recap: Healthcare Dominates A 7 IPO Week

Other stocks mentioned: FUBO, INTZ, KRON, MAACU, MUDSU, NGACU, STTK
Market Watch - 3 months ago

Shares of Spruce Biosciences Inc. rallied in their public debut, as they opened 21% above the initial public offering price. The stock's first trade was at $18.14 at 11:37 a.m.

Market Watch - 3 months ago

Spruce Biosciences Inc. said Friday that its initial public offering, which was upsized by 20%, priced at $15 a share, as the California-based biopharmaceutical company developing treatments f...

Business Wire - 3 months ago

SAN FRANCISCO--(BUSINESS WIRE)---- $SPRB #CAH--Spruce Biosciences Announces Pricing of Upsized Initial Public Offering

About SPRB

Spruce Biosciences, a biopharmaceutical company, focuses on developing and commercializing novel therapies for rare endocrine disorders. The company develops tildacerfont, an non-steroidal therapy, which is in Phase IIb clinical trial for adult patients with classic congenital adrenal hyperplasia (CAH) and in Phase II clinical trial in children with classic CAH. It is also developing tildacerfont for females with polycystic ovary syndrome. The company has a license agreement with Eli Lilly and Company to research, develop, and commercialize com... [Read more...]

Industry
Biotechnology
IPO Date
Oct 9, 2020
Stock Exchange
NASDAQ
Ticker Symbol
SPRB
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecasts

According to 4 analysts, the average rating for SPRB stock is "Buy." The 12-month stock price forecast is 33.75, which is an increase of 53.41% from the latest price.

Price Target
$33.75
(53.41% upside)
Analyst Consensus: Buy